Multimodular biomarker analysis workflow for Diagnosis, PROgnosis and MONitoring of drug treatment response in bladder cancer (http://www.surrey.ac.uk/dipromon/index.htm)
The DIPROMON platform will allow design of a novel patient stratification concept, building the tools, technologies and procedures to apply this concept to the bladder cancer patient scenario. The final stage will be validating the concept in patients with bladder cancer.
The role of LIONEX in Dirpomon is to discover, characterise and produce purified biomarkers for test development.
University of Surrey
Prof Hardev Pandha firstname.lastname@example.org
Emergentec biodevelopment GmbH
AXO Science SAS
Dr Christophe Marquette email@example.com
Austrian Institute of Technology GmbH
Claudia Preininger firstname.lastname@example.org
Gottfried Koehler email@example.com